Status:
UNKNOWN
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
Lead Sponsor:
Assiut University
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
To identify clinical, echocardiographic, and hemodynamic parameters which can predict persistent PH after PMC, and also to determine the impact of persistent PH on the clinical outcomes.
Detailed Description
Pure mitral Stenosis develops in approximately 40% of all patients with rheumatic heart disease, and is frequently complicated by Pulmonary hypertension (PH). Pulmonary hypertension influences symptom...
Eligibility Criteria
Inclusion
- Severe mitral stenosis (mitral valve area ≤1.5cm).
- Significant dyspnea.
- Favorable anatomical characteristics for PMC as assessed by transthoracic echocardiography
Exclusion
- Significant mitral regurgitation (≥ grade II/IV). Bilateral commissural calcification.
- Presence of other lesions which need open heart surgery.
- Wilkins' score \> 12.
- Persistent LA thrombus despite adequate anticoagulation.
- End stage renal or liver disease.
- Patients with severe COPD and other chest problems that might be complicated by pulmonary hypertension per se.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT04083729
Start Date
September 1 2019
End Date
October 1 2021
Last Update
September 10 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.